Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis

por Ducrocq, Gregory, Wallace, Joshua S., Baron, Gabriel, Ravaud, Philippe, Alberts, Mark J., Wilson, Peter W.F., Ohman, Erik Magnus, Brennan, Danielle M., D'Agostino, Ralph B., Bhatt, Deepak L., Steg, Philippe Gabriel
Publicado 2010

Plasma Aldosterone Levels Are Not Associated With Cardiovascular Events Among Patients With High‐Risk Vascular Disease: Insights From the ACCELERATE Trial

por Kumar, Anirudh, Patel, Divyang R., Brennan, Danielle M., Wolski, Kathy E., Lincoff, A. Michael, Ruotolo, Giacomo, McErlean, Ellen, Weerakkody, Govinda, Riesmeyer, Jeffrey S., Nicholls, Stephen J., Nissen, Steven E., Menon, Venu
Publicado 2019

C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV

por Nelson, Adam J., Puri, Rishi, Brennan, Danielle M., Anderson, Todd J., Cho, Leslie, Ballantyne, Christie M., Kastelein, John JP., Koenig, Wolfgang, Kassahun, Helina, Somaratne, Ransi M., Wasserman, Scott M., Nissen, Steven E., Nicholls, Stephen J.
Publicado 2020

Canakinumab to reduce deterioration of cardiac and respiratory function in SARS‐CoV‐2 associated myocardial injury with heightened inflammation (canakinumab in Covid‐19 cardiac inj...

por Sheng, Calvin C, Sahoo, Debasis, Dugar, Siddharth, Prada, Robier Aguillon, Wang, Tom Kai Ming, Abou Hassan, Ossama K, Brennan, Danielle, Culver, Daniel A, Rajendram, Prabalini, Duggal, Abhijit, Lincoff, A Michael, Nissen, Steven E, Menon, Venu, Cremer, Paul C
Publicado 2020

Double-blind randomized proof-of-concept trial of canakinumab in patients with COVID-19 associated cardiac injury and heightened inflammation

por Cremer, Paul C, Sheng, Calvin C, Sahoo, Debasis, Dugar, Siddharth, Prada, Robier Aguillon, Wang, Tom Kai Ming, Hassan, Ossama K Abou, Hernandez-Montfort, Jamie, Wolinsky, David A, Culver, Daniel A, Rajendram, Prabalini, Duggal, Abhijit, Brennan, Danielle M, Wolski, Katherine E, Lincoff, A Michael, Nissen, Steven E, Menon, Venu
Publicado 2021